AbbVie to Buy Apogee Therapeutics for $10.9 Billion

🇺🇸 Bloomberg (US) —

AI Summary

AbbVie is set to acquire Apogee Therapeutics for $10.9 billion, enhancing its dermatology portfolio with new treatments for atopic dermatitis. The acquisition aims to strengthen AbbVie's presence in the dermatology treatment market.

Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

Markets Deals Health AbbVie Apogee Therapeutics acquisition dermatology atopic dermatitis eczema pharmaceutical deal

Read original source →